Literature DB >> 16508623

The potential role of gene expression in the management of primary and metastatic colorectal cancer.

Michael D Alvarado1, Eric H Jensen, Timothy J Yeatman.   

Abstract

BACKGROUND: Although there have been recent advances in treatment of colorectal cancer, microarray technology has the potential to improve the application of these therapies by interrogating tumor-specific molecular "fingerprints."
METHODS: The future applications and benefits of gene expression profiling are discussed.
RESULTS: Potential uses include determining who will benefit from chemotherapy, further classifying patients into responders and nonresponders, predicting apoptotic response, developing classifiers to recognize chemosensitive tumors, identifying genes that portend a poor prognosis, revealing genes associated with metastases, predicting the outcome according to clinical stage, and avoiding surgery in patients who would not benefit from resection.
CONCLUSIONS: Recent research has been aimed at not only finding new molecularly targeted agents, but also identifying specific signatures to predict sensitivity and resistance to therapy. Future care may soon incorporate the data derived from a single microarray chip or similar technology that will describe a patient's tumor, predict prognosis, and direct specific therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16508623     DOI: 10.1177/107327480601300104

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  7 in total

1.  Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer.

Authors:  Junjie Peng; Zhimin Wang; Wei Chen; Yin Ding; Haifeng Wang; Hongjie Huang; Wei Huang; Sanjun Cai
Journal:  Int J Colorectal Dis       Date:  2010-08-13       Impact factor: 2.571

2.  Altered JS-2 expression in colorectal cancers and its clinical pathological relevance.

Authors:  Alfred King-Yin Lam; Vinod Gopalan; Mohammad Reza Nassiri; Kais Kasim; Jayampathy Dissanayake; Johnny Chuek-On Tang; Robert Anthony Smith
Journal:  Mol Oncol       Date:  2011-07-12       Impact factor: 6.603

3.  Predictive and prognostic molecular markers for cancer medicine.

Authors:  Sunali Mehta; Andrew Shelling; Anita Muthukaruppan; Annette Lasham; Cherie Blenkiron; George Laking; Cristin Print
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

4.  Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.

Authors:  Xifeng Wu; Charles Lu; Yuanqing Ye; Joe Chang; Hushan Yang; Jie Lin; Jian Gu; Waun Ki Hong; David Stewart; Margaret R Spitz
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

5.  Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation.

Authors:  Jung Wook Huh; Sung Chun Kim; Insuk Sohn; Sin-Ho Jung; Hee Cheol Kim
Journal:  Oncotarget       Date:  2016-03-29

6.  HIG1 domain family member 1A disrupts proliferation, migration, and invasion of colon adenocarcinoma cells.

Authors:  Zhenyu Xu; Junjie Sun; Yong Mao; Yang Chen; Ting Zhang; Yan Qin; Dong Hua
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 7.  Genomic and oncoproteomic advances in detection and treatment of colorectal cancer.

Authors:  Seamus M McHugh; Jill O'Donnell; Peter Gillen
Journal:  World J Surg Oncol       Date:  2009-04-01       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.